2,995 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Cornerstone Select Advisors LLC

Cornerstone Select Advisors LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,995 shares of the company’s stock, valued at approximately $258,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Centiva Capital LP raised its position in shares of Novo Nordisk A/S by 50.1% in the fourth quarter. Centiva Capital LP now owns 31,367 shares of the company’s stock worth $2,698,000 after acquiring an additional 10,469 shares during the period. Bridgefront Capital LLC purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $341,000. Cantor Fitzgerald L. P. acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $3,017,000. Cary Street Partners Financial LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $2,413,000. Finally, Baird Financial Group Inc. raised its stake in shares of Novo Nordisk A/S by 0.4% during the 4th quarter. Baird Financial Group Inc. now owns 865,877 shares of the company’s stock worth $74,483,000 after buying an additional 3,283 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $66.32 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm has a market capitalization of $297.63 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The stock’s fifty day moving average is $70.60 and its two-hundred day moving average is $87.08. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Guggenheim downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Dbs Bank cut Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Finally, BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.